Skip to main content
Egyptian Liver Journal
Download PDF

Role of liver biopsy versus non-invasive biomarkers for diagnosis of significant fibrosis and cirrhosis: a web-based survey

Egyptian Liver Journal volume 11, Article number: 94 (2021) Cite this article

Abstract

Background

Liver biopsy is the standard reference for staging hepatic fibrosis. Non-invasive methods for assessment of hepatic fibrosis and cirrhosis are becoming increasingly popular.

Objective

We aimed at exploring the change in practice regarding the use of liver biopsy and non-invasive methods for staging hepatic fibrosis and cirrhosis among hepatologists.

Methods

We performed a survey-based study that recruited hepatologists from various Egyptian institutions. Physicians were deemed eligible if they had a degree in internal medicine with hepatology as a subspecialty. We utilized an online-based survey that assessed the acceptability and reliability of liver biopsy, serum biomarkers, and radiological tools for evaluating liver fibrosis and cirrhosis.

Results

A total of 573 responses were retrieved (response rate = 80.3%). Out of them, 58% were having more than 15 years of experience as a hepatologist.

Liver biopsy is still considered the gold standard for assessment of hepatic fibrosis and cirrhosis by 61% of participants. Liver biopsy was accepted by 44% of their patients. 84% reported the need for a more practical alternative to liver biopsy to assess disease progression or response to treatment. 78.34% of participants know serum biomarkers, 84.08% reported that they were acceptable by their patients, 37.79% thought they are reliable. 95.4% were familiar with radiological methods of non-invasive assessment of hepatic fibrosis, 89.1% reported that radiological methods were acceptable by their patients, 62% think that they are reliable and 78% reported they were applicable in clinical practice. Sixty-five percent think that combining non-invasive methods is better than using a single method. Forty percent of participants thought that radiological methods are easier to use for assessment of hepatic fibrosis followed by a combination of non-invasive methods, serum biomarkers, and liver biopsy respectively.

Conclusion

In conclusion, liver biopsy is still considered the most reliable method for evaluation and staging of liver cirrhosis by hepatologists in Egyptian institutions, despite the modest acceptance by the patients. Nonetheless, non-invasive methods are gaining acceptance by Egyptian physicians and patients, and most of them consider these methods as reliable and applicable tools for predicting the course of liver cirrhosis.

Introduction

Liver cirrhosis is the end stage of various chronic liver diseases that has the cardinal features of extensive hepatic fibrosis, scarring, and regenerative nodules; which, in return, lead to irreversible deformity of physiological hepatic architecture [1]. Liver cirrhosis is a serious, relatively prevalent, cause of global morbidity and mortality; recent estimates demonstrated that liver cirrhosis accounted for nearly 2.5% of the total global deaths in 2017—around 1.3 million deaths—, ranking it as the 11th leading attribute of global mortality [2,3,4]. The distribution of liver cirrhosis shows notable ethnic and socioeconomic variations, with the highest prevalence reported among low-income African countries [4]. Liver cirrhosis is a major cause of disability and represents a global economic burden as well. Several hepatic disorders can lead to the development of liver cirrhosis such as chronic viral hepatitis, alcoholism, and non-alcoholic steatohepatitis [5].

Early recognition and monitoring of liver cirrhosis are the cornerstones for optimal treatment outcomes and reducing the risk of complications in cirrhotic patients [6, 7]. To date, liver biopsy is the gold standard procedure for diagnostic and prognostic evaluation of liver cirrhosis, previous reports showed that liver biopsy finding is the most consistent, independent, predictor of outcomes of chronic liver diseases [8, 9]. Nonetheless, the invasive and painful nature of liver biopsy is a major disadvantage that can result in various post-procedure complications; other disadvantages of liver biopsy include its high cost and the possibility of sampling errors during specimen retrieval and handling [10]. Thus, the use of liver biopsy in local settings can be limited by poor reliability and acceptance of the procedure by both healthcare physicians and patients [11]. Recently, non-invasive markers have gained momentum for evaluation of liver cirrhosis; over the recent two decades, various serological, ultrasound-based, and magnetic resonance (MR)-based markers were evaluated as potential alternatives for liver biopsy in the setting of liver cirrhosis [10]. Markers, such as serum biomarkers algorithm [12, 13], transient elastography [14], shear wave elastography [15], and MR elastography [16] exhibited high performance and reproducibility for evaluation of liver cirrhosis and prediction of clinical outcomes. Thus, non-invasive methods are increasingly accepted by healthcare physicians as reliable and well-validated methods for the assessment of liver cirrhosis [17]. Nonetheless, limited data are available regarding the acceptance and reliability of non-invasive methods for the assessment of liver cirrhosis in developing countries with a high prevalence of liver cirrhosis, like Egypt. This survey-based study aimed to provide real-life data concerning the level of acceptance and reliability of non-invasive methods for the assessment of liver fibrosis and cirrhosis among hepatologists from Egyptian institutions.

Materials and methods

Study design and population

We performed a survey-based study that recruited hepatologists from various Egyptian institutions. The survey was sent to participants through an online website (www.surveymonkey.com) after they gave their approval of participation in the present study via email. We utilized a non-probability, convenience, sampling technique to recruit eligible physicians. The preparation of the present manuscript runs in compliance with the STROBE statement [18].

Data collection

The survey assessed the level of acceptance and reliability of different methods for assessment of liver fibrosis and cirrhosis among hepatologists. The survey consisted of 47 questions that were administrated in the English language. The first part consisted of 8 questions assessing the demographic characteristics, and the level of experience of participants. The second part, assessed the acceptability and reliability of liver biopsy amongst participants using 14, mainly 5-Likert scale, questions; while the third part assessed the acceptability and reliability of serum biomarkers and consists of 5 questions. The fourth part assessed the acceptability and reliability of radiological markers and consisted of 7 questions. Finally, the fifth part was used to assess the utilization of combination methods and participants’ attitudes towards them. Before the implementation of the study, a preliminary pilot test for different sections of the questionnaire was done among twenty potential participants. This was performed to check the validity and clarity of the structured questions as well as to estimate the time needed to complete the survey. Accordingly, some questions about attitude and practice were restructured. The results of the pilot study were excluded from data analysis.

Statistical analysis

Data were entered and validated using Microsoft Excel 2019, while the statistical analysis was done using the statistical package for the social sciences (SPSS, windows version 22). All continuous quantitative data were presented in mean and standard deviation (SD). While categorical data were presented in frequencies and percentages. 

Results

The present cross-sectional study included 573 participants with an age range from 25 to 75 years old and male predominance (71.55%). Out of them, 58% were having more than 15 years of experience as a hepatologist. Most of the participants (61%) agreed that liver biopsy is still considered the gold standard for the assessment of hepatic fibrosis and cirrhosis. However, they admitted that only 44% of patients clearly accepted liver biopsy. Most of the participants did not think they need a liver biopsy for diagnosis of significant fibrosis and cirrhosis in viral hepatitis (56%), on the other hand, 45% of participants thought they still need a liver biopsy for diagnosis of significant fibrosis and cirrhosis in non-viral chronic liver diseases. Only 8% of participants saw discordance between results of liver biopsy (histopathology report) and clinical findings. If the histopathology report was discordant with clinical findings, most of the participants (60%) used non-invasive methods “radiological methods or serum biomarkers”, 34.19% asked for a second opinion from another pathologist and 6.71% repeated liver biopsy. Most of the participants (88%) agreed that they can diagnose cirrhosis easily using clinical, laboratory, and radiological evaluation. On the other hand, 51.58% of participants diagnose significant fibrosis easily (clinically, laboratory, and radiologically). Interestingly, 66% of participants did not think a liver biopsy is required for diagnosing cirrhosis. On the other hand, (39%) a liver biopsy is required to diagnose significant hepatic fibrosis. The majority of participants (84%) thought they need a more practical alternative to liver biopsy to assess liver disease progression or response to treatment (Table 1).

Table 1 Hepatologists’ attitude towards the use of liver biopsy for diagnosis of significant fibrosis and cirrhosis
Full size table

The majority of participants (78.34%) knew non-invasive (blood/serum) fibrosis markers for assessment of hepatic fibrosis but only 37.79% of participants thought that serum biomarkers are reliable. Most of the participants (84.08%) thought serum biomarkers are acceptable by patients while only 38% used them for assessment of hepatic fibrosis. Most of the participants (66%) preferred to use transient elastography for assessment of hepatic fibrosis, 45% used a combination of serum biomarkers and elastography, 31.42% used blood/serum biomarkers alone, and 7.86% used magnetic resonance elastography. Most of the participants (95.42%) were familiar with radiological methods for non-invasive assessment of hepatic fibrosis. Sixty-two percent of participants thought that radiological methods are reliable, 89.1% thought that they are acceptable by patients and 78% considered radiological methods to be easily applicable in clinical practice. The most commonly used methods for assessment were FibroScan, ultrasound, computed tomography, ultrasound-based elastography, magnetic resonance imaging (MRI), and MRI-based elastography respectively. Most of the participants (87.58%) considered radiological methods for non-invasive assessment of hepatic fibrosis easy to use (Tables 2 and 3).

Table 2 Hepatologists’ attitude towards the use of serum markers for diagnosis of significant fibrosis and cirrhosis
Full size table
Table 3 Hepatologists’ attitude towards the use of radiological methods for diagnosis of significant fibrosis and cirrhosis
Full size table

Despite that, 65% of participants thought combinations of methods are more beneficial for non-invasive assessment of hepatic fibrosis than using a single method, only 39.37% of participants used them frequently. Forty percent of participants thought that radiological methods are easier to use for assessment of hepatic fibrosis followed by the combination of non-invasive methods, serum biomarkers, and liver biopsy respectively (Table 4).

Table 4 Hepatologists’ attitude towards the use of combination tools for diagnosis of significant fibrosis and cirrhosis
Full size table

Discussion

In this web-based survey, we assessed the level of acceptance and reliability of liver biopsy and non-invasive methods for the assessment of hepatic fibrosis and cirrhosis among hepatologists. Our results demonstrated that the majority of Egyptian hepatologists still consider liver biopsy as the gold standard tool for diagnosis and staging of liver fibrosis and cirrhosis. Liver biopsy results had a high level of acceptance and reliability among Egyptian hepatologists. Liver biopsies were reported to have a modest level of acceptance among patients. Despite the high level of acceptance, most hepatologists stated that there is a need for less-invasive alternatives, especially when serial evaluation of liver fibrosis/cirrhosis is a need. Most of the participants in the present survey stated that they knew the utility of serum biomarkers and radiological tools as non-invasive methods for assessment of liver cirrhosis; these methods are widely accepted by the physicians and the patients and are considered as reliable and applicable tools. The participants agreed that there is a need for a national guideline that governs the utilization of non-invasive methods for the assessment of liver fibrosis.

Liver cirrhosis is a major public health burden in Egypt, which harbors the largest number of patients with chronic hepatitis C worldwide [19]; previous epidemiological studies demonstrated that Egypt is ranked as the first leading country regarding cirrhosis-related mortality worldwide [20]. Therefore, evaluation and monitoring of liver cirrhosis account for a considerable proportion of routine clinical practice of Egyptian hepatologists; nevertheless, limited data are available concerning the frequency and sequence of different tools for assessment of liver fibrosis. Previous reports demonstrated that the utilization of liver biopsy has been significantly declined in Egypt over the past decades [21]. Such findings can be attributed to the limitations of liver biopsy such as invasive nature and high risk of post-procedure complications [10]. However, it is still unclear whether the decline in the utilization and acceptance of liver biopsy is consistent among different institutions in the country. Some studies about these non-invasive methods, especially in Egypt, showed that APRI, FIB4, and GUCI can be used as good predictors of liver fibrosis in chronic hepatitis C [22]. In this report, we highlighted that majority of Egyptian hepatologists still consider liver biopsy as the gold standard tool for diagnosis and staging of liver cirrhosis; the biopsy also had a high level of acceptance and reliability among the Egyptian hepatologists, despite the modest acceptance by the patients. To our knowledge, no previous published studies have assessed the acceptability and reliability of liver biopsy among Egyptian hepatologists. However, our results are contrary to reports from Europe [11] and Canada [23], which showed that many hepatologists have shifted to radiological tools for the evaluation and monitoring of chronic liver diseases.

As mentioned before, non-invasive markers have gained momentum for the evaluation of liver cirrhosis over the recent two decades and many of these tools were well-validated in large cohort studies [10, 12,13,14,15,16]. Recent reports demonstrated that there is a notable increase in the acceptance of non-invasive tools among hepatologists in routine clinical practice [24], which is attributed to the simplicity of these tools and the avoidance of complications associated with liver biopsy; besides, many of these tools are readily available, even in limited-resources area, and cheaper than standard liver biopsy procedure [25]. In the present survey, we found that non-invasive methods are gaining acceptance by Egyptian physicians and patients, and most of them consider these methods as reliable and applicable tools for predicting the course of liver cirrhosis. Notably, we found that hepatologists prefer radiological methods over serum biomarkers, and considered them as easier and cheaper methods for evaluation and staging of liver cirrhosis. This study, however, has some limitations. Although web-based surveys may have advantages related to the speed and cost of data collection as well as data quality, they may be biased by low and selective participation. The Likert scale, based on overall impression, may provide more variable results when applied across hepatologists and gastroenterologists from different institutions; the potential effect of the institution, in addition to individual readers, warrants future evaluation. Areas that should be targeted in future research include validation of promising novel imaging technologies (ultrasound-based, and magnetic resonance (MR)-based markers), longitudinal studies to validate the performance of noninvasive surrogates for monitoring fibrosis progression (or regression) over time, the definition of the role of combined vs. sequential noninvasive test approaches to optimize accuracy, validation of non-invasive methods for screening fibrosis and cirrhosis in at-risk groups (e.g., diabetic patients) and in the general population and finally validation in special populations (e.g., pediatric subjects).

Conclusion

In conclusion, liver biopsy is still considered as the most reliable method for evaluation and staging of liver cirrhosis by hepatologists in Egyptian institutions, despite the modest acceptance by the patients. Nonetheless, non-invasive methods are gaining acceptance by Egyptian physicians and patients, and most of them consider these methods as reliable and applicable tools for predicting the course of liver cirrhosis. Notably, we found that hepatologists prefer radiological methods over serum biomarkers, and considered them as easier and cheaper methods for evaluation and staging of liver cirrhosis. Owing to the scarcity in the published literature, further studies with a well-planned design and multinational collaboration are still needed.

Availability of data and materials

The dataset used in the current study are available from the corresponding author on reasonable request.

Abbreviations

MR:

Magnetic resonance

STROBE:

STrengthening the Reporting of OBservational studies in Epidemiology

SPSS:

Statistical Package for the Social Sciences

SD:

Standard deviation

MRI:

Magnetic resonance imaging

APRI:

Aspartate aminotransferase-to-platelet ratio index

FIB4:

Fibrosis-4 index

GUCI:

Göteborg University Cirrhosis Index

References

  1. Tsochatzis EA, Bosch J, Burroughs AK (2014) Liver cirrhosis. Lancet 383(9930):1749–1761

    Article  Google Scholar 

  2. Sepanlou SG, Safiri S, Bisignano C, Ikuta KS, Merat S, Saberifiroozi M, Poustchi H, Tsoi D, Colombara DV, Abdoli A, Adedoyin RA (2020) The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol 5(3):245–266

    Article  Google Scholar 

  3. Mokdad AA, Lopez AD, Shahraz S, Lozano R, Mokdad AH, Stanaway J, Murray CJ, Naghavi M (2014) Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med 12(1):1–24

    Article  Google Scholar 

  4. Asrani SK, Devarbhavi H, Eaton J, Kamath PS (2019) Burden of liver diseases in the world. J Hepatol 70(1):151–171

    Article  Google Scholar 

  5. Ge PS, Runyon BA (2016) Treatment of Patients with Cirrhosis. N Engl J Med. 375(8):767–777

    Article  CAS  Google Scholar 

  6. Nusrat S, Khan MS, Fazili J, Madhoun MF (2014) Cirrhosis and its complications: evidence based treatment. World J Gastroenterol: WJG 20(18):5442

    Article  CAS  Google Scholar 

  7. Ginés P, Quintero E, Arroyo V, Terés J, Bruguera M, Rimola A, Caballería J, Rodés J, Rozman C (1987) Compensated cirrhosis: natural history and prognostic factors. Hepatology. 7(1):122–128

    Article  Google Scholar 

  8. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, Haflidadottir S (2015) Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 149(2):389–397

    Article  Google Scholar 

  9. Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, Hultcrantz R (2015) Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 61(5):1547–1554

    Article  CAS  Google Scholar 

  10. Chin JL, Pavlides M, Moolla A, Ryan JD (2016) Non-invasive markers of liver fibrosis: adjuncts or alternatives to liver biopsy? Front Pharmacol 7:159

    Article  Google Scholar 

  11. Cadranel JF, Rufat P, Degos F (2000) Practices of liver biopsy in France: results of a prospective nationwide survey. Hepatology. 32(3):477–481

    Article  CAS  Google Scholar 

  12. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K (2007) The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 45(4):846–854

    Article  CAS  Google Scholar 

  13. Afdhal NH, Nunes D (2004) Evaluation of liver fibrosis: a concise review. Off J Am College of Gastroenterol| ACG 99(6):1160–1174

    Article  Google Scholar 

  14. Boursier J, Konaté A, Gorea G, Reaud S, Quemener E, Oberti F, Hubert-Fouchard I, Dib N, Calès P (2008) Reproducibility of liver stiffness measurement by ultrasonographic elastometry. Clin Gastroenterol Hepatol 6(11):1263–1269

    Article  Google Scholar 

  15. Friedrich-Rust M, Wunder K, Kriener S, Sotoudeh F, Richter S, Bojunga J, Herrmann E, Poynard T, Dietrich CF, Vermehren J, Zeuzem S (2009) Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology. 252(2):595–604

    Article  Google Scholar 

  16. Castera L (2012) Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 142(6):1293–1302

    Article  Google Scholar 

  17. Boursier J, Brochard C, Bertrais S, Michalak S, Gallois Y, Fouchard-Hubert I, Oberti F, Rousselet MC, Calès P (2014) Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C. Aliment Pharmacol Ther 40(2):178–188

    Article  CAS  Google Scholar 

  18. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP (2014) Strobe initiative. The Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg 12(12):1495–1499

    Article  Google Scholar 

  19. Elgharably A, Gomaa AI, Crossey MM, Norsworthy PJ, Waked I, Taylor-Robinson SD (2017) Hepatitis C in Egypt–past, present, and future. Int J General Med 10:1

    Article  Google Scholar 

  20. Wong MCS, Huang J (2018) The growing burden of liver cirrhosis: implications for preventive measures. Hepatol Int 12(3):201–203. https://doi.org/10.1007/s12072-018-9865-y Epub 2018 Apr 20. PMID: 29679258

    Article  PubMed  Google Scholar 

  21. Hassan M, Helal N, Aboushousha T (2018) Comparative study of liver biopsy results in Egypt over three decades. Gen Med Open 2. https://doi.org/10.15761/GMO.1000132

  22. Yousry A et al (2016) Fibroscan, APRI, FIB4 and GUCI: role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection. Arab J Gastroentrol 17(2):78–83

    Article  Google Scholar 

  23. Aljawad M, Yoshida EM, Uhanova J, Marotta P, Chandok N (2013) Percutaneous liver biopsy practice patterns among Canadian hepatologists. Can J Gastroenterol 27(11):e31–e34

    Article  Google Scholar 

  24. Patel K, Sebastiani G (2020) Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Reports 2(2):100067

    Article  Google Scholar 

  25. Castera L (2011) Non-invasive assessment of liver fibrosis in chronic hepatitis C. Hepatol Int 5(2):625–634

    Article  Google Scholar 

Download references

Acknowledgements

None

Funding

This is a non-funded work.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Al-Azhar University, Nasr City, Cairo, 11884, Egypt

    Mohamed Alboraie, Zakarya Shady, Ahmed Eliwa, Mahmoud A. Allam & Fathy Elghamry

  2. Endemic Medicine and Hepatology Department, Cairo University, Cairo, Egypt

    Marwa Khairy, Aisha Elsharkawy & Gamal Esmat

  3. Department of Public Health and Community Medicine, Cairo University, Cairo, Egypt

    Noha Asem

  4. Research and Health Development, Ministry of Health and Population, Cairo, Egypt

    Noha Asem

  5. Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt

    Mohamed El Kassas

  6. Department of Clinical Pathology, Al-Azhar University, Cairo, Egypt

    Abdelaleem A. Elgendy

  7. Arab Academy for Science, Technology and Maritime Transport, Alexandria, Egypt

    Hanaa Nagdy

  8. Internal Medicine Department, Misr University For Science and Technology, Cairo, Egypt

    Amira R. El-Ansary

  9. Clinical Biochemistry, Faculty of Medicine, Cairo University, Cairo, Egypt

    Mohamed Ibrahem

  10. Hepatology, Gastroenterology, and Infectious Diseases, Al-Azhar University, Cairo, Egypt

    Abdelhalim Elsherif

  11. Department of Internal Medicine, Faculty of Medicine, Kuwait University, Al-Jabriya, Kuwait

    Fuad Hassan

  12. Hepatology and Tropical Medicine Department, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt

    Mohamed Hassany

  13. Ministry of Health and Population, Cairo, Egypt

    Mohamed Hassany

Authors
  1. Mohamed Alboraie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marwa Khairy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aisha Elsharkawy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Noha Asem
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mohamed El Kassas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Abdelaleem A. Elgendy
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hanaa Nagdy
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zakarya Shady
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ahmed Eliwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Amira R. El-Ansary
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mohamed Ibrahem
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Mahmoud A. Allam
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Abdelhalim Elsherif
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Fathy Elghamry
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Fuad Hassan
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Mohamed Hassany
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Gamal Esmat
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

On behalf of the Egyptian Liver Fibrosis Study Group

Contributions

MA, MK, AE, and NA conceptualized the idea and designed the study. ME, AAE, HN, ZK, AE, ARE, MI, MAA, and AE collected the data. NA did statistical analysis. MA, HN, and ARE drafted the final manuscript. FE, FH, MH, and GE reviewed the manuscript for certain intellectual points. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Mohamed Alboraie.

Ethics declarations

Ethics approval and consent to participate

This study was done in accordance with the ethical standards of Helsinki Declaration and its later amendments. The study was approved by the Ethics Committee of the faculty of medicine, AL-Azhar University. Informed consent was obtained from all participants.

Consent for publication

All authors agree to the journal rules for publications.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alboraie, M., Khairy, M., Elsharkawy, A. et al. Role of liver biopsy versus non-invasive biomarkers for diagnosis of significant fibrosis and cirrhosis: a web-based survey. Egypt Liver Journal 11, 94 (2021). https://doi.org/10.1186/s43066-021-00166-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s43066-021-00166-9

Keywords

  • Non-invasive tools
  • Liver biopsy
  • Cirrhosis
  • Acceptability
  • Reliability
  • Egypt